Accelr8, Complete Genomics Post Big Half-Year Gains in Share Price

Accelr8 jumped more than 300 percent and Complete Genomics more than doubled in the first half of the year, while Rosetta Genomics, Nanosphere, and Vermillion slumped.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.